Minute Insight: NHS Employs OCTAPUS AI To Predict Lung Cancer Recurrence

The OCTAPUS AI study demonstrated that machine learning was a better tool than typical assessments used to predict recurrence of non-small cell lung cancer.

Minute Insight
The OCTAPUS-AI study did not make use of molluscs • Source: Informa/Alamy

Results of from the fantastically named OCTAPUS AI study showed artificial intelligence could accurately and efficiently spot patients who are likely to suffer from recurrence following treatment for non-small cell lung cancer (NSCLC).

NSCLC can be treated if it is caught early and compared to small cell lung cancer, and five-year survival...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Minute Insights

Minute Insight: Haemonetics Buys OpSens To Add Fiber-Optic Sensors For Intervention

 
• By 

Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.

Minute Insight: Best Buy Will Sell Dexcom CGM

 
• By 

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

 

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

 
• By 

Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.

More from Medtech Insight

Execs On The Move: July 14–18, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Medtech M&A Resurges: How To Define Startup Exit Strategy

 

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.